L87.2 Elastosis perforans serpiginosa

Name of the Condition

• Elastosis perforans serpiginosa

Summary

Elastosis perforans serpiginosa is a rare skin condition characterized by the abnormal extrusion of elastic fibers through the epidermis, resulting in distinctive papular or keratotic lesions. These lesions typically appear in a linear or serpiginous pattern and may be associated with underlying systemic conditions or genetic factors. The condition involves the transepidermal elimination of elastic tissue, leading to visible skin changes.

Causes

The exact cause of elastosis perforans serpiginosa is not fully understood but is thought to involve dysregulation of elastic fiber metabolism or impaired skin barrier function. Some cases may be associated with genetic mutations, connective tissue disorders, or underlying systemic conditions such as Down syndrome, Ehlers-Danlos syndrome, or pseudoxanthoma elasticum. The extrusion of elastic fibers through the epidermis is believed to be a reactive process to abnormal material accumulation in the skin.

Risk Factors

• Genetic predisposition: Familial cases have been reported.
• Underlying systemic conditions: Associations with Down syndrome, Ehlers-Danlos syndrome, or pseudoxanthoma elasticum.
• Age: Typically occurs in young adults, though cases in children or older adults are possible.
• Skin trauma or irritation: May trigger or exacerbate lesions in susceptible individuals.

Symptoms

• Linear or serpiginous papules, often with a central keratotic plug.
• Predilection for the neck, face, or extremities.
• Asymptomatic or mild pruritus in some cases.
• Lesions may be grouped or arranged in a characteristic pattern.

Diagnosis

Diagnosis is typically based on clinical presentation and histopathological examination. A skin biopsy showing transepidermal elimination of elastic fibers is confirmatory. Clinical correlation with underlying conditions or genetic factors may support the diagnosis. Dermoscopy or imaging may be used to evaluate lesion characteristics, but histology remains the gold standard.

Treatment Options

Treatment is often aimed at managing symptoms and addressing underlying causes. Options may include topical or intralesional corticosteroids, retinoids, or cryotherapy. In some cases, lesions may resolve spontaneously. Management of associated systemic conditions is important for patients with comorbidities. Referral to a dermatologist is recommended for persistent or severe cases.

Prognosis and Follow-Up

The prognosis is generally good, with many cases resolving spontaneously over months to years. Lesions may persist or recur, particularly in individuals with underlying conditions. Regular follow-up with a dermatologist is advised to monitor for changes or complications. Long-term outcomes depend on the presence of associated systemic factors.

Complications

• Persistent or recurrent lesions.
• Cosmetic concerns due to visible skin changes.
• Potential association with underlying connective tissue disorders, which may have their own complications.
• Rarely, secondary infection or scarring from lesion manipulation.

Lifestyle & Prevention

• Avoid skin trauma or irritation to reduce lesion exacerbation.
• Use gentle skincare products to maintain skin barrier integrity.
• Protect skin from excessive sun exposure, as UV damage may affect elastic fiber health.
• Address underlying systemic conditions through appropriate medical management.

When to Seek Professional Help

Seek medical evaluation if lesions are painful, rapidly spreading, or associated with systemic symptoms. Consult a dermatologist for persistent or atypical lesions, especially if there is a family history of similar conditions or known connective tissue disorders. Early diagnosis can help manage symptoms and rule out other dermatologic conditions.

Tips for Medical Coders

When coding for elastosis perforans serpiginosa (ICD10CM: L87.2), ensure documentation supports the clinical diagnosis, including lesion characteristics, distribution, and any associated systemic conditions. Note the presence of transepidermal elimination of elastic fibers if confirmed histologically. Avoid coding for unrelated conditions or comorbidities unless explicitly documented. Verify that the code aligns with the patient’s specific clinical presentation and diagnostic findings.